Transdermal clonidine for ameliorating tamoxifen-induced hot flashes

Richard M. Goldberg, Charles Lawrence Loprinzi, Judith R. O'Fallon, Michael H. Veeder, Angela W. Miser, James A. Mailliard, John C. Michalak, Ann Marie Dose, Ken M. Rowland, Nora L. Burnham

Research output: Contribution to journalArticle

250 Citations (Scopus)

Abstract

Purpose: To determine the efficacy of transdermal clonidine for alleviating tamoxifen-induced hot flashes in women with a history of breast cancer. Patients and Methods: A randomized, double-blind, crossover design was used in this prospective study. Women with a history of breast cancer who were receiving tamoxifen and suffering from hot flashes were potentially eligible for this protocol study. Results: Clonidine did reduce hot-flash frequency to a degree that was statistically impressive (P < .0001), but clinically moderate (20% reduction from baseline). It also decreased hot- flash severity (P = .02, 10% reduction from baseline). Clonidine was related to increased mouth dryness (P < .001), constipation (P < .02), itchiness under the patch (P < .01), and drowsiness (P < .05). Conclusion: Better means are needed to alleviate hot flashes among patients in whom estrogen therapy is contraindicated.

Original languageEnglish (US)
Pages (from-to)155-158
Number of pages4
JournalJournal of Clinical Oncology
Volume12
Issue number1
StatePublished - Jan 1994

Fingerprint

Hot Flashes
Clonidine
Tamoxifen
Breast Neoplasms
Xerostomia
Sleep Stages
Constipation
Cross-Over Studies
Estrogens
Prospective Studies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Goldberg, R. M., Loprinzi, C. L., O'Fallon, J. R., Veeder, M. H., Miser, A. W., Mailliard, J. A., ... Burnham, N. L. (1994). Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. Journal of Clinical Oncology, 12(1), 155-158.

Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. / Goldberg, Richard M.; Loprinzi, Charles Lawrence; O'Fallon, Judith R.; Veeder, Michael H.; Miser, Angela W.; Mailliard, James A.; Michalak, John C.; Dose, Ann Marie; Rowland, Ken M.; Burnham, Nora L.

In: Journal of Clinical Oncology, Vol. 12, No. 1, 01.1994, p. 155-158.

Research output: Contribution to journalArticle

Goldberg, RM, Loprinzi, CL, O'Fallon, JR, Veeder, MH, Miser, AW, Mailliard, JA, Michalak, JC, Dose, AM, Rowland, KM & Burnham, NL 1994, 'Transdermal clonidine for ameliorating tamoxifen-induced hot flashes', Journal of Clinical Oncology, vol. 12, no. 1, pp. 155-158.
Goldberg RM, Loprinzi CL, O'Fallon JR, Veeder MH, Miser AW, Mailliard JA et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. Journal of Clinical Oncology. 1994 Jan;12(1):155-158.
Goldberg, Richard M. ; Loprinzi, Charles Lawrence ; O'Fallon, Judith R. ; Veeder, Michael H. ; Miser, Angela W. ; Mailliard, James A. ; Michalak, John C. ; Dose, Ann Marie ; Rowland, Ken M. ; Burnham, Nora L. / Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. In: Journal of Clinical Oncology. 1994 ; Vol. 12, No. 1. pp. 155-158.
@article{d3cce9a79dbc4d31a0a296527cced815,
title = "Transdermal clonidine for ameliorating tamoxifen-induced hot flashes",
abstract = "Purpose: To determine the efficacy of transdermal clonidine for alleviating tamoxifen-induced hot flashes in women with a history of breast cancer. Patients and Methods: A randomized, double-blind, crossover design was used in this prospective study. Women with a history of breast cancer who were receiving tamoxifen and suffering from hot flashes were potentially eligible for this protocol study. Results: Clonidine did reduce hot-flash frequency to a degree that was statistically impressive (P < .0001), but clinically moderate (20{\%} reduction from baseline). It also decreased hot- flash severity (P = .02, 10{\%} reduction from baseline). Clonidine was related to increased mouth dryness (P < .001), constipation (P < .02), itchiness under the patch (P < .01), and drowsiness (P < .05). Conclusion: Better means are needed to alleviate hot flashes among patients in whom estrogen therapy is contraindicated.",
author = "Goldberg, {Richard M.} and Loprinzi, {Charles Lawrence} and O'Fallon, {Judith R.} and Veeder, {Michael H.} and Miser, {Angela W.} and Mailliard, {James A.} and Michalak, {John C.} and Dose, {Ann Marie} and Rowland, {Ken M.} and Burnham, {Nora L.}",
year = "1994",
month = "1",
language = "English (US)",
volume = "12",
pages = "155--158",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Transdermal clonidine for ameliorating tamoxifen-induced hot flashes

AU - Goldberg, Richard M.

AU - Loprinzi, Charles Lawrence

AU - O'Fallon, Judith R.

AU - Veeder, Michael H.

AU - Miser, Angela W.

AU - Mailliard, James A.

AU - Michalak, John C.

AU - Dose, Ann Marie

AU - Rowland, Ken M.

AU - Burnham, Nora L.

PY - 1994/1

Y1 - 1994/1

N2 - Purpose: To determine the efficacy of transdermal clonidine for alleviating tamoxifen-induced hot flashes in women with a history of breast cancer. Patients and Methods: A randomized, double-blind, crossover design was used in this prospective study. Women with a history of breast cancer who were receiving tamoxifen and suffering from hot flashes were potentially eligible for this protocol study. Results: Clonidine did reduce hot-flash frequency to a degree that was statistically impressive (P < .0001), but clinically moderate (20% reduction from baseline). It also decreased hot- flash severity (P = .02, 10% reduction from baseline). Clonidine was related to increased mouth dryness (P < .001), constipation (P < .02), itchiness under the patch (P < .01), and drowsiness (P < .05). Conclusion: Better means are needed to alleviate hot flashes among patients in whom estrogen therapy is contraindicated.

AB - Purpose: To determine the efficacy of transdermal clonidine for alleviating tamoxifen-induced hot flashes in women with a history of breast cancer. Patients and Methods: A randomized, double-blind, crossover design was used in this prospective study. Women with a history of breast cancer who were receiving tamoxifen and suffering from hot flashes were potentially eligible for this protocol study. Results: Clonidine did reduce hot-flash frequency to a degree that was statistically impressive (P < .0001), but clinically moderate (20% reduction from baseline). It also decreased hot- flash severity (P = .02, 10% reduction from baseline). Clonidine was related to increased mouth dryness (P < .001), constipation (P < .02), itchiness under the patch (P < .01), and drowsiness (P < .05). Conclusion: Better means are needed to alleviate hot flashes among patients in whom estrogen therapy is contraindicated.

UR - http://www.scopus.com/inward/record.url?scp=0028088855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028088855&partnerID=8YFLogxK

M3 - Article

C2 - 8270972

AN - SCOPUS:0028088855

VL - 12

SP - 155

EP - 158

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -